Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individualizing chemotherapy for solid tumors--is there any alternative?

I A Cree1, C M Kurbacher

  • 1Department of Pathology, Institute of Ophthalmology, University College London, UK.

Anti-Cancer Drugs
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WHO 2022 classification of penile and scrotal cancers: updates and evolution.

Histopathology·2022
Same author

Targeting EGFR and PI3K pathways in ovarian cancer.

British journal of cancer·2013
Same author

Identification of markers of prostate cancer progression using candidate gene expression.

British journal of cancer·2011
Same author

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

British journal of cancer·2011
Same author

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.

British journal of cancer·2010
Same author

Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines.

Toxicology in vitro : an international journal published in association with BIBRA·2010

Individualizing cancer treatment shows promise for improving outcomes. Cellular chemosensitivity assays combined with molecular analysis may help select optimal therapies for patients with solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tumor complexity drives heterogeneity in treatment response, a major challenge in solid tumor chemotherapy.
  • Despite theoretical appeal, past attempts at individualizing chemotherapy have yielded limited progress.
  • Disparate molecular profiles within tumor types suggest personalized approaches are necessary.

Purpose of the Study:

  • To review alternative methods for individualizing cancer therapy.
  • To outline requirements for introducing new therapeutic strategies.
  • To explore the potential of molecular analysis and cellular assays in predicting chemosensitivity.

Main Methods:

  • Review of current literature on molecular carcinogenesis and drug resistance.
  • Discussion of emerging cellular chemosensitivity assays, including ATP-tumor chemosensitivity assay.

Related Experiment Videos

  • Consideration of molecular measurement techniques allied with functional assays.

    • Main Results:

    • Molecular analysis alone is not yet sufficient to predict chemosensitivity for current agents.
    • Newly developed cellular chemosensitivity assays show potential for optimizing patient therapy.
    • Development of diverse, biologically logical in vitro tested regimens is needed for common tumor types.

    Conclusions:

    • Individualized cancer therapy holds considerable potential benefits.
    • Cellular chemosensitivity assays coupled with molecular data may offer a viable path to personalized treatment selection.
    • Further development and validation of in vitro testing platforms are crucial for advancing personalized oncology.